Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Cellectar Biosciences (NV40) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Dexamethasone, Rituximab, Iopofosine I 131, Cyclophosphamate, Clr 131Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinaemia Refractory, Waldenstrom Macroglobulinemia With Nodal DiseasePhase IIINot Yet RecruitingEvaluation of Iopofosine I 131 vs. R-CD in WM PatientsJul 30, 2026―
Iopofosine I 131, Clr 125Breast CancerPhase IRecruitingPhase 1 Study of CLR 125 in Triple Negative Breast CancerNov 13, 2025
Clr 131High-Grade GliomaPhase IActive Not RecruitingNovel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGGOct 28, 2022―
Clr 131Osteosarcoma, Neuroblastoma, Rhabdomyosarcoma, Pediatric Solid Tumor, Ewing Sarcoma, Dipg, Pediatric Lymphoma, Pediatric Brain TumorPhase IActive Not RecruitingDose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasMar 20, 2018―
Iopofosine I 131 Single Dose, Iopofosine I 131 Multiple Dose, Iopofosine I 131 Fractionated DoseMultiple Myeloma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia, Central Nervous System LymphomaPhase IIActive Not RecruitingStudy of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromOct 28, 2016―
Dexamethasone, I-131-Clr1404Multiple MyelomaPhase ICompletedDose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple MyelomaOct 22, 2014―
I-124-Clr1404GlioblastomaPhase IITerminatedImaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent GlioblastomaJul 08, 2013―
Nov-205Hepatitis CPhase IICompletedA Trial of NOV-205 in Hepatitis C Patients Who Failed Standard TherapyJan 26, 2010―
Carboplatin, Paclitaxel, Nov-002Non Small Cell Lung CancerPhase IIICompletedStudy of NOV-002 in Combination With Chemotherapy to Treat Lung CancerJun 29, 2006―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Cellectar Biosciences Inc (DE:NV40) have in its pipeline
Cellectar Biosciences DE:NV40 is currently developing the following drugs: Dexamethasone, Rituximab, Iopofosine I 131, Cyclophosphamate, Clr 131, Iopofosine I 131, Clr 125, Clr 131, Iopofosine I 131 Single Dose, Iopofosine I 131 Multiple Dose, Iopofosine I 131 Fractionated Dose, Dexamethasone, I-131-Clr1404, I-124-Clr1404, Nov-205, Carboplatin, Paclitaxel, Nov-002. These drug candidates are in various stages of clinical development as the company works toward FDA approval.